David W. Boulton

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

R. Holman, Adrian F. Hernandez, H. Heerspink, 2019, Cardiovascular Diabetology.